scispace - formally typeset
M

Maria Carafa

Researcher at Sapienza University of Rome

Publications -  110
Citations -  3503

Maria Carafa is an academic researcher from Sapienza University of Rome. The author has contributed to research in topics: Niosome & Nanocarriers. The author has an hindex of 34, co-authored 102 publications receiving 2922 citations. Previous affiliations of Maria Carafa include University of Chieti-Pescara.

Papers
More filters
Journal ArticleDOI

Niosomes from 80s to present: the state of the art.

TL;DR: This up-to-date review deals with composition, preparation, characterization/evaluation, advantages, disadvantages and application of niosomes.
Journal ArticleDOI

Anticancer activity of liposomal bergamot essential oil (BEO) on human neuroblastoma cells

TL;DR: This work formulated BEO liposomes that improved the water solubility of the phytocomponents and increased their anticancer activity in vitro against human SH-SY5Y neuroblastoma cells, and the results warrant further investigation of BEOliposomes for in vivo applications.
Journal ArticleDOI

Lidocaine-loaded non-ionic surfactant vesicles: characterization and in vitro permeation studies

TL;DR: Diffusion experiments showed that the flux of charged lidocaine through Silastic membrane was possible only after the vesicle encapsulation, and the possible reason of the remarkable lower e.e. of the drug was negligible was investigated by means of fluorescence quenching experiments.
Journal ArticleDOI

Ultradeformable liposomes as multidrug carrier of resveratrol and 5-fluorouracil for their topical delivery

TL;DR: Resveratrol and 5-fluorouracil co-loaded ultradeformable liposomes could be a new nanomedicine for the treatment of squamous cell carcinoma, i.e., actinic keratosis, Bowen's disease, and keratoacanthoma.
Journal ArticleDOI

Non-ionic surfactant vesicles in pulmonary glucocorticoid delivery: characterization and interaction with human lung fibroblasts.

TL;DR: In vitro investigation of non-ionic surfactant vesicles for pulmonary delivery of glucocorticoids determined a noticeable increase of the drug anti-inflammatory activity by reducing the secretion of both constitutive and interleukin-1β-stimulated nerve growth factor.